eXoZymes posts Q3 net loss of $2.24 million as operating expenses rise 21%
EXOZ•eXoZymes reported a third-quarter 2026 net loss of $2.24 million as operating expenses rose 21% year over year to $3.05 million. It ended the quarter with $3.26 million in cash, expected to support operations through the beginning of 2027.
1. Quarterly results
Exozymes reported a third-quarter 2026 net loss of $2.24 million, while operating expenses increased 21% year over year to $3.05 million. Quarter-end cash and cash equivalents totaled $3.26 million, which the company expects to support operations through the beginning of 2027.
2. Product development
Technology transfer to Curia began in the fourth quarter of 2026, targeting larger-scale NCT manufacturing in 2027. Two additional supplement candidates completed proof of concept, and Product SAPPHIRE began scale-up activities.




